Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...